Vivani Medical (VANI) 10-Q 13 May 21 2021 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2021	May 10, 2021
Document Information [Line Items]
Entity Registrant Name	SECOND SIGHT MEDICAL PRODUCTS INC
Entity Central Index Key	0001266806
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Shell Company	false
Document Type	10-Q
Document Period End Date	Mar. 31, 2021
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q1
Amendment Flag	false
Entity File Number	001-36747
Entity Incorporation, State or Country Code	CA
Entity Tax Identification Number	02-0692322
Entity Address Address Line1	13170 Telfair Avenue
Entity Address, City or Town	Sylmar
Entity Address, Postal Zip Code	91342
City Area Code	818
Local Phone Number	833-5000
Entity Address, State or Province	CA
Entity Common Stock, Shares Outstanding (in shares)		27,909,149
Document Quarterly Report	true
Document Transition Report	false
Common Stock [Member]
Document Information [Line Items]
Title of 12(b) Security	Common Stock
Trading Symbol	EYES
Security Exchange Name	NASDAQ
Warrant [Member]
Document Information [Line Items]
Title of 12(b) Security	Warrants
Trading Symbol	EYESW
Security Exchange Name	NASDAQ

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 26,862	$ 3,177
Prepaid expenses and other current assets	759	1,092
Total current assets	27,621	4,269
Property and equipment, net	154	174
Right-of-use assets, net	351
Deposits and other assets	19	17
Total assets	28,145	4,460
Current liabilities:
Accounts payable	1,607	486
Accrued expenses	1,220	875
Accrued compensation expense	199	173
Accrued clinical trial expenses	1,212	1,063
Current operating lease liabilities	167
Current debt	2,200	2,200
Contract liabilities	335	335
Total current liabilities	6,940	5,132
Long term operating lease liabilities	199
Total liabilities	7,139	5,132
Commitments and contingencies
Stockholders’ equity (deficit):
Preferred stock, no par value, 10,000 shares authorized; none outstanding
Common stock, no par value; 300,000 shares authorized; shares issued and outstanding: 27,908 and 23,214 as of March 31, 2021 and December 31, 2020, respectively	294,592	270,126
Additional paid-in capital	49,333	49,314
Accumulated other comprehensive loss	(412)	(448)
Accumulated deficit	(322,507)	(319,664)
Total stockholders’ equity (deficit)	21,006	(672)
Total liabilities and stockholders’ equity (deficit)	$ 28,145	$ 4,460

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parenthetical) - $ / shares	Mar. 31, 2021	Dec. 31, 2020
Statement Of Financial Position [Abstract]
Preferred stock, no par value (in dollars per share)
Preferred stock, shares authorized (in shares)	10,000,000	10,000,000
Preferred stock, shares outstanding (in shares)	0	0
Common stock, no par value (in dollars per share)
Common stock, shares authorized (in shares)	300,000,000	300,000,000
Common stock, shares issued (in shares)	27,908,000	23,214,000
Common stock, shares outstanding (in shares)	27,908,000	23,214,000

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Operating expenses:
Research and development, net of grants	$ 334	$ 3,887
Clinical and regulatory, net of grants	37	914
Selling and marketing		701
General and administrative	2,472	2,021
Restructuring charges		1,381
Total operating expenses	2,843	8,904
Loss from operations	(2,843)	(8,904)
Interest income		18
Net loss	$ (2,843)	$ (8,886)
Net loss per common share – basic and diluted	$ (0.12)	$ (0.57)
Weighted average common shares outstanding – basic and diluted	23,537	15,649

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Loss (unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Statement Of Income And Comprehensive Income [Abstract]
Net loss	$ (2,843)	$ (8,886)
Other comprehensive income (loss):
Foreign currency translation adjustments	36	19
Comprehensive loss	$ (2,807)	$ (8,867)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) - USD ($) $ in Thousands	Total	Common Stock [Member]	Accumulated Other Comprehensive Loss [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]
Balance beginning at Dec. 31, 2019	$ 7,725	$ 264,008	$ (562)	$ 48,613	$ (304,784)
Balance beginning (in shares) at Dec. 31, 2019		15,643,000
Repurchase of fractional shares in connection with reverse stock split	(11)	$ (11)
Repurchase of fractional shares in connection with reverse stock split (in shares)		(2,000)
Issuance of shares of common stock	6	$ 6
Issuance of shares of common stock (in shares)		1,000
Release of restricted stock units (shares)		15,000
Stock-based compensation expense	279			279
Net loss	(8,886)				(8,886)
Foreign currency translation adjustment	19		19
Balance ending at Mar. 31, 2020	(1,318)	$ 264,003	(543)	48,892	(313,670)
Balance ending (in shares) at Mar. 31, 2020		15,657,000
Balance beginning at Dec. 31, 2020	$ (672)	$ 270,126	(448)	49,314	(319,664)
Balance beginning (in shares) at Dec. 31, 2020	23,214,000	23,214,000
Issuance of shares of common stock in underwritten public offering	$ 24,451	$ 24,451
Issuance of shares of common stock in underwritten public offering (in shares)		4,650,000
Warrants exercised	15	$ 15
Warrants exercised (in shares)		44,000
Stock-based compensation expense	19			19
Net loss	(2,843)				(2,843)
Foreign currency translation adjustment	36		36
Balance ending at Mar. 31, 2021	$ 21,006	$ 294,592	$ (412)	$ 49,333	$ (322,507)
Balance ending (in shares) at Mar. 31, 2021	27,908,000	27,908,000

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Cash flows from operating activities:
Net loss	$ (2,843)	$ (8,886)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	20	106
Stock-based compensation	19	279
Non-cash lease expense	16	3
Restructuring charges-inventory and fixed asset impairment		1,115
Changes in operating assets and liabilities:
Accounts receivable		455
Inventories		(112)
Prepaid expenses and other assets	332	(610)
Accounts payable	1,158	497
Accrued expenses	345	286
Accrued compensation expenses	26	(1,813)
Accrued clinical trial expenses	149	26
Net cash used in operating activities	(778)	(8,654)
Cash flows from investing activities:
Purchases of property and equipment		(331)
Net cash used in investing activities		(331)
Cash flows from financing activities:
Net proceeds from sale of common stock and/or warrants	24,466	6
Repurchase of fractional shares in connection with reverse stock split		(11)
Net cash provided by (used in) financing activities	24,466	(5)
Effect of exchange rate changes on cash and cash equivalents	(3)	2
Cash and cash equivalents:
Net increase (decrease)	23,685	(8,988)
Balance at beginning of period	3,177	11,327
Balance at end of period	$ 26,862	$ 2,339

Organization and Business Opera

Organization and Business Operations	3 Months Ended
	Mar. 31, 2021
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Organization and Business Operations	1. Organization and Business Operations Second Sight Medical Products, Inc. (“Second Sight,” the “Company,” “we,” “us,” “our” or similar terms) has developed, manufactured and marketed implantable visual prosthetics that are intended to deliver useful artificial vision to blind individuals. We are a recognized global leader in neuromodulation devices for blindness, and are committed to developing new technologies to treat the broadest population of sight-impaired individuals. Leveraging our 20 years of experience in neuromodulation for vision, we are developing the Orion ® • We have a good safety profile • The efficacy data is encouraging No peer-reviewed data is available yet for the Orion system. We are currently negotiating the clinical and regulatory pathway to commercialization with the FDA as part of the Breakthrough Devices Program. Our principal offices are located in Los Angeles, California. In 2007, Second Sight formed Second Sight Medical Products (Switzerland) Sàrl, initially to manage clinical trials and sales and marketing in Europe, the Middle East and Asia-Pacific, and more recently for the research of future technologies. As the laws of Switzerland require at least two corporate stockholders, Second Sight Medical Products (Switzerland) Sàrl is 99.5% owned directly by us and 0.5% owned by an executive of Second Sight as of March 31, 2021. Accordingly, Second Sight Medical Products (Switzerland) Sàrl is considered 100% owned for financial statement purposes and is consolidated with Second Sight for all periods presented. We have closed our foreign operations and expect final dissolution of this entity in the third quarter of 2021. Product and Clinical Development Plans By further developing our visual cortical prosthesis, Orion, we believe we may be able to significantly expand our market to include nearly all profoundly blind individuals. The principal notable exceptions for potential use of the Orion are those who are blind due to otherwise currently treatable diseases, individuals who are born blind, or blindness due to direct damage of the visual cortex, which is rare. However, of the estimated 36 million blind people worldwide, there are approximately 5.8 million people who are legally blind due to causes that are not otherwise treatable. We continue to develop and refine our estimates of the potential addressable market size as we evaluate the commercial prospects for Orion using a combination of published sources, third party market research, and physician feedback. We currently estimate over 500,000 individuals in the US are legally blind due to retinitis pigmentosa, glaucoma, diabetic retinopathy, optic nerve disease and eye injury. Of this population, we estimate the potential US addressable market is between 50,000 and 100,000 individuals with bi-lateral blindness at the light-perception level or worse. Our marketing approvals by the FDA and other regulatory agencies will ultimately determine the subset of these patients who are eligible for the Orion based on our clinical trials and the associated results. Our objective in designing and developing the Orion visual prosthesis system is to bypass the optic nerve and directly stimulate the part of the brain responsible for human vision. In November 2017, the FDA granted Breakthrough Devices Program designation for the Orion. This designation is given to a few select medical devices in order to provide more effective treatment of life-threatening or irreversibly debilitating diseases or conditions. This program is intended to help patients have more timely access to these medical devices by expediting their development, assessment, and review. On February 26, 2021, the U.S. Food and Drug Administration (FDA) approved the Argus 2s Retinal Prosthesis System, a redesigned set of external hardware (glasses and video processing unit) initially for use in combination with previously implanted Argus II systems for the treatment of retinitis pigmentosa (RP). The Company expects that the Argus 2s will be adapted to be the external system for the next generation Orion Visual Cortical Prosthesis System currently under development. In addition to ergonomic improvements, the Argus 2s system offers significantly more processing power, potentially allowing for improved video processing. A decision on when or if to begin production of the newly approved hardware is under evaluation. Liquidity and Capital Resources From inception, our operations have been funded primarily through the sales of our common stock and warrants, as well as from the issuance of debt, convertible debt, research and clinical grants, and limited product revenue generated from the sale of our Argus II product. Funding of our business since 2019 has been primarily provided by: • On March 23, 2021, we closed our private placement to seven institutional investors of 4,650,000 shares of common stock at a price of $6.00 per share for aggregate net proceeds of approximately $24.5 million • On December 8, 2020, we borrowed $1 million from Gregg Williams, Chairman of the Board of Directors of the Company and $1.2 million from two unaffiliated shareholders • On May 5, 2020, we closed our underwritten public offering of 7,500,000 shares of common stock at an offering price of $1.00 per share for aggregate net proceeds of approximately $6.7 million We were awarded a $1.6 million grant (with the intent to fund $6.4 million over five years subject to annual review and approval) from the National Institutes of Health (NIH) to fund the “Early Feasibility Clinical Trial of a Visual Cortical Prosthesis” that commenced in January 2018. Our second year grant of $1.4 million was approved on April 6, 2021. As of March 31, 2021 we recorded $0.5 million of deferred grant costs receivable, included in prepaid expenses and other current assets. Our financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. Our ability to continue as a going concern is dependent on our ability to develop profitable operations through implementation of our business initiatives and/or raise additional capital, however, there can be no assurances that we will be able to do so. We have been notified by the Nasdaq stock market regarding our non-compliance with one of the continued listing requirements of the Nasdaq Capital Market and as a result we could be subject to delisting if we do not regain compliance within the compliance period (or the compliance period as may be extended).

Basis of Presentation, Signific

Basis of Presentation, Significant Accounting Policies and Recent Accounting Pronouncements	3 Months Ended
	Mar. 31, 2021
Disclosure Text Block [Abstract]
Basis of Presentation, Significant Accounting Policies and Recent Accounting Pronouncements	2. Basis of Presentation, Significant Accounting Policies and Recent Accounting Pronouncements Basis of Presentation These unaudited interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) and following the requirements of the United States Securities and Exchange Commission (“SEC”) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by GAAP can be condensed or omitted. In our opinion, the unaudited interim financial statements have been prepared on the same basis as the audited financial statements and include all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of our financial position and our results of operations and cash flows for periods presented. These statements do not include all disclosures required by GAAP and should be read in conjunction with our financial statements and accompanying notes for the fiscal year ended December 31, 2020, contained in our Annual Report on Form 10-K filed with the SEC on March 16, 2021. The results of the interim periods are not necessarily indicative of the results expected for the full fiscal year or any other interim period or any future year or period. Reverse Stock Split On December 31, 2019 we effected a reverse stock split of the outstanding shares of our no par value common stock and outstanding warrants to purchase our common stock by a ratio of 1-for-8 (1:8). The common stock and warrants began trading on the Nasdaq Capital Market on a split-adjusted basis on January 6, 2020. The accompanying consolidated financial statements and notes thereto give retrospective effect to the reverse stock split for all periods presented. All issued and outstanding common stock, options and warrants exercisable for common stock, restricted stock units, and per share amounts contained in our consolidated financial statements have been retrospectively adjusted. Significant Accounting Policies Segment Reporting. Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. Our chief operating decision-maker reviews financial information presented on a consolidated basis. Accordingly, we consider ourselves to be in a single reporting segment, specifically the discovery, development and commercialization of visual prosthetics for profoundly blind individuals. We historically managed our Argus II and Orion programs on a consolidated basis within this single operating segment and do not assess the performance of our product lines or geographic regions on other measures of income or expense, such as program expense, operating income or net income. Our underlying technology consists of hardware components (implanted and wearable) and software. A vast majority of this underlying technology was shared between the Argus II and Orion branded systems. While we have ceased production and marketing the Argus II product we are developing Orion as a next generation product with potential to treat a broader market of blind individuals. On March 31, 2020, due to the COVID-19 pandemic and related inability to secure additional funding, we laid off the majority of our employees and reduced our operating expenses significantly to allow for our continuing business operations. Due to our focus on Orion and wind down of selling and marketing activities related to Argus II, we recorded impairment charges to our inventory of $0.5 million and $0.7 million to our fixed assets used primarily for Argus activities. We also incurred $0.2 million in severance payments. We continue to advance the development of our Orion technology and are exploring various strategic options to accelerate development of Orion. Our significant accounting policies are set forth in Note 2 of the financial statements in our Annual Report on Form 10-K for the year ended December 31, 2020. Recently Issued Accounting Pronouncements We do not believe that any recently issued, but not yet effective, accounting standards, if adopted, will have a material effect on the financial statements.

Concentration of Risk

Concentration of Risk	3 Months Ended
	Mar. 31, 2021
Risks And Uncertainties [Abstract]
Concentration of Risk	3. Concentration of Risk Credit Risk Financial instruments that subject us to concentrations of credit risk consist primarily of cash, money market funds, and trade accounts receivable. We maintain cash and money market funds with financial institutions that we deem reputable. We extended differing levels of credit to our customers, and typically did not require collateral. Foreign Operations The accompanying condensed consolidated financial statements as of March 31, 2021 and December 31, 2020 include assets amounting to $62,000 and $18,000, respectively, relating to operations of our subsidiary based in Switzerland.

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2021
Fair Value Disclosures [Abstract]
Fair Value Measurements	4. Fair Value Measurements The authoritative guidance with respect to fair value establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three levels, and requires that assets and liabilities carried at fair value be classified and disclosed in one of three categories, as presented below. Disclosure as to transfers in and out of Levels 1 and 2, and activity in Level 3 fair value measurements, is also required. Level 1. Observable inputs such as quoted prices in active markets for an identical asset or liability that we have the ability to access as of the measurement date. Financial assets and liabilities utilizing Level 1 inputs include active-exchange traded securities and exchange-based derivatives. Level 2. Inputs, other than quoted prices included within Level 1, which are directly observable for the asset or liability or indirectly observable through corroboration with observable market data. Financial assets and liabilities utilizing Level 2 inputs include fixed income securities, non-exchange based derivatives, mutual funds, and fair-value hedges. Level 3. Unobservable inputs in which there is little or no market data for the asset or liability which requires the reporting entity to develop its own assumptions. Financial assets and liabilities utilizing Level 3 inputs include infrequently-traded non-exchange-based derivatives and commingled investment funds, and are measured using present value pricing models. Cash equivalents, which includes money market funds, are the only financial instrument measured and recorded at fair value on our consolidated balance sheet, and they are valued using Level 1 inputs. Assets measured at fair value on a recurring basis are as follows (in thousands): Total Level 1 Level 2 Level 3 March 31, 2021 (unaudited): Money market funds $ 26,698 $ 26,698 $ — $ — December 31, 2020: Money market funds $ 3,122 $ 3,122 $ — $ —

Selected Balance Sheet Detail

Selected Balance Sheet Detail	3 Months Ended
	Mar. 31, 2021
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Selected Balance Sheet Detail	5. Selected Balance Sheet Detail Inventories, net Inventories consisted of the following (in thousands): March 31, December 31, 2021 2020 Raw materials $ — $ — Work in process — — Finished goods 295 295 295 295 Allowance for excess and obsolete inventory and impairment charge (295 ) (295 ) Inventories, net $ — $ — Property and equipment, net Property and equipment consisted of the following (in thousands): March 31, December 31, 2021 2020 Laboratory equipment $ 584 $ 584 Computer hardware and software 69 69 653 653 Accumulated depreciation and amortization (499 ) (479 ) Property and equipment, net $ 154 $ 174 As a result of our decision to cease marketing of Argus II we recorded an impairment of $0.7 million during the period ended March 31, 2020 related to our fixed assets. Debt On December 8, 2020, we borrowed $1 million from Gregg Williams, Chairman of the Board of Directors of the Company and $1.2 million from two unaffiliated shareholders. Each promissory note is unsecured and accrues interest at a rate of twelve percent (12%) per annum beginning on receipt of the loan amounts. Principal and accrued interest under the promissory notes, are payable on December 31, 2021. As of March 31, 2021 and December 31, 2020, accrued interest amounted to $82,000 and $17,000, respectively, and is recorded in accrued expenses. Contract Liabilities Contract liabilities consisted of the following (in thousands): Beginning balance as of December 31, 2020 $ 335 Consideration received in advance of revenue recognition — Revenue recognized — Ending balance as of March 31, 2021 $ 335 Product Warranties A summary of activity of our warranty liabilities, which are included in accrued expenses, for the period ended March 31, 2021 is presented below: Beginning balance as of December 31, 2020 $ 200 Additions — Settlements — Adjustments and other — Ending balance as of March 31, 2021 $ 200 Right-of-use assets and operating lease liabilities We lease certain office space and equipment for our use. Leases with an initial term of 12 months or less are not recorded on the balance sheet. Lease costs are recognized in the income statement over the lease term on a straight-line basis. Depreciation is computed using the straight-line method over the estimated useful life of the respective assets. The depreciable life of assets and leasehold improvements are limited by the expected lease term. Our lease agreements do not contain any material residual value guarantees or restrictive covenants. As most of our leases do not provide an implicit rate, we used our estimated incremental borrowing rate of 10% based on the information available at commencement date in determining the present value of lease payments. On May 18, 2020 we entered into a Letter Agreement with Sylmar Biomedical Park, LLC (the “Landlord”), pursuant to which the parties agreed to accelerate the expiration dates of our existing leases (the “Leases”), to a date not later than June 18, 2020 (“Accelerated Termination Date”). We agreed to pay the Landlord (i) $210,730 to bring the Leases current (the “Owed Rent”) and to remit (ii) a one-time early termination fee in the amount of $150,000 (the “Early Termination Amount”). Prior to the early termination agreed in this letter we were obligated to pay aggregate base rent of approximately $0.9 million and common area maintenance expenses for the term remaining under the Leases through the respective expiration dates in February 2022 and April 2023. The Landlord acknowledged that as of the date of the Letter Agreement the Owed Rent and the Early Termination Amount constituted all amounts owing to the Landlord under the Leases. On January 22, 2021, we entered into a lease agreement, effective February 1, 2021, to sub-lease office space to replace our existing headquarters. We will pay $17,000 per month, increasing to $17,500 per month on February 1, 2022, plus operating expenses, to lease 17,290 square feet of office space at 13170 Telfair Avenue, Sylmar, CA 91342. Additionally, we receive full rent abatement for March 2021, and half rent abatement for March 2022. The sub-lease is for two years and two months. We are not affiliates of, are not related to, or otherwise have any other relationship with, the other parties, other than the lease. The Company evaluated the lease amendment under the provisions of ASC 842. Information related to the Company’s right-of-use assets and related lease liabilities are as followings (in thousands, except for remaining lease term and discount rate): Year ending December 31: 2021 (9 months remaining) $ 153 2022 201 2023 52 Total lease payments 406 Less imputed interest (40) Total lease liabilities $ 366 Other supplemental information: Current operating lease liabilities $ 167 Long term operating lease liabilities 199 Total lease liabilities $ 366 Discount rate 10% For the three months ended March 31, 2021 For the three months ended 2020 Cash paid for operating lease liabilities $ 17 $ 121 Rent expense, including common area maintenance charges, was $22,000 and $123,000 during the three-month periods ended March 31, 2021 and 2020, respectively.

Equity Securities

Equity Securities	3 Months Ended
	Mar. 31, 2021
Stockholders Equity Note [Abstract]
Equity Securities	6. Equity Securities Potentially Dilutive Common Stock Equivalents As of March 31, 2021 and 2020, we excluded the potentially dilutive securities summarized below, which entitle the holders thereof to potentially acquire shares of common stock, from our calculations of net loss per share and weighted average common shares outstanding, as their effect would have been anti-dilutive (in thousands). March 31, 2021 2020 Common stock warrants issued to underwriter in connection with May 2020 offering 10 — Common stock warrants issued in connection with March 2017 rights offering 1,706 1,706 Common stock warrants issued in connection with February 2019 rights offering 5,976 5,976 Common stock options 182 890 Restricted stock units — 25 7,874 8,597

Warrants

Warrants	3 Months Ended
	Mar. 31, 2021
Warrants And Rights Note Disclosure [Abstract]
Warrants	7. Warrants On February 22, 2019, we completed a registered rights offering to existing stockholders in which we sold approximately 5,976,000 units at $5.792 per unit, which was the adjusted closing price of our common stock on that date. Each Unit consisted of a share of our common stock and a warrant to purchase an additional share of our stock for $11.76. The warrants had a five-year life and trade on Nasdaq under the symbol EYESW. On March 6, 2017, we completed a registered rights offering to existing stockholders in which we sold approximately 1,706,000 units at $11.76 per unit, which was the adjusted closing price of our common stock on that date. Each unit consisted of a share of our common stock and a warrant to purchase an additional share of our stock for $11.76. The warrants have a five-year life and have been approved for trading on Nasdaq under the symbol EYESW. We extended the term of 1.7 million warrants issued in our March 2017 rights offering by approximately two years effective as of February 15, 2019 as part of our February 2019 rights offering. We determined the fair value of the March 2017 Warrants immediately before and after the modification. The fair value of the March 2017 Warrants after the modification was increased by approximately $1.6 million, resulting in an accounting adjustment to additional paid-in capital and accumulated deficit in the consolidated statements of shareholders’ equity. The assumptions used in the determination of fair value of the warrants before and after the extension included a risk free interest rate of 2.50% and 2.49%, expected volatility of 81% and 82%, and expected lives of 3.08 years and 5.08 years, respectively and 0% dividend yields for both. Upon close of our May 2020 registered offering we issued 375,000 warrants to our underwriter. These warrants are exercisable at $1.25 per share and expire on May 5, 2025. At March 31, 2021, 10,125 of the warrants are still outstanding. A summary of warrants activity for the three months ended March 31, 2021 is presented below (in thousands, except per share and contractual life data). Number of Shares Weighted Average Exercise Price Per Share Weighted Average Remaining Contractual Life (in Years) Warrants outstanding as of December 31, 2020 7,759 $ 11.66 3.21 Issued — Exercised (67 ) 11.76 Forfeited or expired — Warrants outstanding as of March 31, 2021 7,692 $ 11.75 2.96 Warrants exercisable as of March 31, 2021 7,692 $ 11.75 2.96 The warrants outstanding as of March 31, 2021 had $71,000 in intrinsic value.

Stock-Based Compensation

Stock-Based Compensation	3 Months Ended
	Mar. 31, 2021
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock-Based Compensation	8. Stock-Based Compensation A summary of stock option activity under our 2011 Equity Incentive Plan (“2011 Plan”) for the three months ended March 31, 2021 is presented below (in thousands, except per share and contractual life data). Number of Shares Weighted Average Exercise Price Per Share Weighted Average Remaining Contractual Life (in Years) Options outstanding as of December 31, 2020 196 $ 15.48 7.65 Granted — $ — Exercised — $ — Forfeited or expired (14 ) $ 12.95 Options outstanding as of March 31, 2021 182 $ 15.68 7.35 Options exercisable as of March 31, 2021 133 $ 19.79 6.85 The estimated aggregate intrinsic value of stock options exercisable as of March 31, 2021 was $160,000. As of March 31, 2021, there was $0.1 million of total unrecognized compensation cost related to outstanding stock options that will be recognized over a weighted average period of 2.70 years. We adopted an employee stock purchase plan in June 2015 for all eligible employees. At March 31, 2021 the available number of shares that may be issued under the plan is 77,031. Stock-based compensation expense recognized for stock-based awards in the condensed consolidated statements of operations for the three months ended March 31, 2021 and 2020 was as follows (in thousands): Three Months Ended March 31, 2021 2020 Cost of sales $ — $ — Research and development 5 102 Clinical and regulatory 9 15 Selling and marketing — 41 General and administrative 5 121 Total $ 19 $ 279

Litigation, Claims and Assessme

Litigation, Claims and Assessments	3 Months Ended
	Mar. 31, 2021
Disclosure Text Block [Abstract]
Litigation, Claims and Assessments	10. Litigation, Claims and Assessments Three oppositions filed by Pixium Vision are pending in the European Patent Office, each challenging the validity of a European patent owned by us. The outcome of the challenges are not certain, however, if successful, they may affect our ability to block competitors from utilizing our patented technology. We believe a successful challenge will not have a material effect on our ability to manufacture and sell our products, or otherwise have a material effect on our operations. As described in the Company’s 10-K for the year ended December 31, 2020, the Company had entered into a Memorandum of Understanding (“MOU”) for a proposed business combination with Pixium Vision SA (“Pixium”). In response to a press release by Pixium dated March 24, 2021, and subsequent communications between us and Pixium, our Board of Directors determined that the business combination with Pixium was not in the best interest of our shareholders. On April 1, 2021, we gave notice to Pixium that we were terminating the MOU between the parties and seeking an amicable resolution of termination amounts that may be due, however no assurance can be given that an amicable resolution will be reached. We accrued $1,000,000 of liquidated damages as contemplated by the MOU in accounts payable as of March 31, 2021 and remitted that amount to Pixium in April 2021. Pixium indicated that it considered this termination wrongful, rejected the Company’s offers, claimed six million Euros in damages (about $7.3 million in USD), and indicated it would pursue litigation. We cannot predict the outcome of this dispute In November 2020, we and Pixium retained Oppenheimer & Co. Inc. as placement agent for a proposed private placement of securities in connection with the Business Combination. On April 1, 2021, we received an invoice from Oppenheimer for more than $1.86 million. This amount includes a requested commission of 6.5% on $27.9 million raised in the private placed. We believe that claims for payment presented by this invoice are without merit. We are party to litigation arising in the ordinary course of business. It is our opinion that the outcome of such matters will not have a material effect on our results of operations, however, the results of litigation and claims are inherently unpredictable. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors

Significant Accounting Policies

Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2021
Disclosure Text Block [Abstract]
Significant Accounting Policies	Basis of Presentation These unaudited interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) and following the requirements of the United States Securities and Exchange Commission (“SEC”) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by GAAP can be condensed or omitted. In our opinion, the unaudited interim financial statements have been prepared on the same basis as the audited financial statements and include all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of our financial position and our results of operations and cash flows for periods presented. These statements do not include all disclosures required by GAAP and should be read in conjunction with our financial statements and accompanying notes for the fiscal year ended December 31, 2020, contained in our Annual Report on Form 10-K filed with the SEC on March 16, 2021. The results of the interim periods are not necessarily indicative of the results expected for the full fiscal year or any other interim period or any future year or period.
Reverse Stock Split	Reverse Stock Split On December 31, 2019 we effected a reverse stock split of the outstanding shares of our no par value common stock and outstanding warrants to purchase our common stock by a ratio of 1-for-8 (1:8). The common stock and warrants began trading on the Nasdaq Capital Market on a split-adjusted basis on January 6, 2020. The accompanying consolidated financial statements and notes thereto give retrospective effect to the reverse stock split for all periods presented. All issued and outstanding common stock, options and warrants exercisable for common stock, restricted stock units, and per share amounts contained in our consolidated financial statements have been retrospectively adjusted.
Segment Reporting	Segment Reporting. Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. Our chief operating decision-maker reviews financial information presented on a consolidated basis. Accordingly, we consider ourselves to be in a single reporting segment, specifically the discovery, development and commercialization of visual prosthetics for profoundly blind individuals. We historically managed our Argus II and Orion programs on a consolidated basis within this single operating segment and do not assess the performance of our product lines or geographic regions on other measures of income or expense, such as program expense, operating income or net income. Our underlying technology consists of hardware components (implanted and wearable) and software. A vast majority of this underlying technology was shared between the Argus II and Orion branded systems. While we have ceased production and marketing the Argus II product we are developing Orion as a next generation product with potential to treat a broader market of blind individuals. On March 31, 2020, due to the COVID-19 pandemic and related inability to secure additional funding, we laid off the majority of our employees and reduced our operating expenses significantly to allow for our continuing business operations. Due to our focus on Orion and wind down of selling and marketing activities related to Argus II, we recorded impairment charges to our inventory of $0.5 million and $0.7 million to our fixed assets used primarily for Argus activities. We also incurred $0.2 million in severance payments. We continue to advance the development of our Orion technology and are exploring various strategic options to accelerate development of Orion. Our significant accounting policies are set forth in Note 2 of the financial statements in our Annual Report on Form 10-K for the year ended December 31, 2020.
Recent Accounting Pronouncements	Recently Issued Accounting Pronouncements We do not believe that any recently issued, but not yet effective, accounting standards, if adopted, will have a material effect on the financial statements. Debt On December 8, 2020, we borrowed $1 million from Gregg Williams, Chairman of the Board of Directors of the Company and $1.2 million from two unaffiliated shareholders. Each promissory note is unsecured and accrues interest at a rate of twelve percent (12%) per annum beginning on receipt of the loan amounts. Principal and accrued interest under the promissory notes, are payable on December 31, 2021. As of March 31, 2021 and December 31, 2020, accrued interest amounted to $82,000 and $17,000, respectively, and is recorded in accrued expenses.

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2021
Fair Value Disclosures [Abstract]
Schedule of Fair Value, Assets Measured on Recurring Basis	Assets measured at fair value on a recurring basis are as follows (in thousands): Total Level 1 Level 2 Level 3 March 31, 2021 (unaudited): Money market funds $ 26,698 $ 26,698 $ — $ — December 31, 2020: Money market funds $ 3,122 $ 3,122 $ — $ —

Selected Balance Sheet Detail (

Selected Balance Sheet Detail (Tables)	3 Months Ended
	Mar. 31, 2021
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Schedule of Inventories	Inventories consisted of the following (in thousands): March 31, December 31, 2021 2020 Raw materials $ — $ — Work in process — — Finished goods 295 295 295 295 Allowance for excess and obsolete inventory and impairment charge (295 ) (295 ) Inventories, net $ — $ —
Schedule of Property and Equipment	Property and equipment consisted of the following (in thousands): March 31, December 31, 2021 2020 Laboratory equipment $ 584 $ 584 Computer hardware and software 69 69 653 653 Accumulated depreciation and amortization (499 ) (479 ) Property and equipment, net $ 154 $ 174
Schedule of Contract Liabilities	Contract liabilities consisted of the following (in thousands): Beginning balance as of December 31, 2020 $ 335 Consideration received in advance of revenue recognition — Revenue recognized — Ending balance as of March 31, 2021 $ 335
Schedule of Activity in the Company's Warranty Liabilities	A summary of activity of our warranty liabilities, which are included in accrued expenses, for the period ended March 31, 2021 is presented below: Beginning balance as of December 31, 2020 $ 200 Additions — Settlements — Adjustments and other — Ending balance as of March 31, 2021 $ 200
Schedule of Lease Assets and Liabilities	The Company evaluated the lease amendment under the provisions of ASC 842. Information related to the Company’s right-of-use assets and related lease liabilities are as followings (in thousands, except for remaining lease term and discount rate): Year ending December 31: 2021 (9 months remaining) $ 153 2022 201 2023 52 Total lease payments 406 Less imputed interest (40) Total lease liabilities $ 366 Other supplemental information: Current operating lease liabilities $ 167 Long term operating lease liabilities 199 Total lease liabilities $ 366 Discount rate 10% For the three months ended March 31, 2021 For the three months ended 2020 Cash paid for operating lease liabilities $ 17 $ 121

Equity Securities (Tables)

Equity Securities (Tables)	3 Months Ended
	Mar. 31, 2021
Stockholders Equity Note [Abstract]
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	As of March 31, 2021 and 2020, we excluded the potentially dilutive securities summarized below, which entitle the holders thereof to potentially acquire shares of common stock, from our calculations of net loss per share and weighted average common shares outstanding, as their effect would have been anti-dilutive (in thousands). March 31, 2021 2020 Common stock warrants issued to underwriter in connection with May 2020 offering 10 — Common stock warrants issued in connection with March 2017 rights offering 1,706 1,706 Common stock warrants issued in connection with February 2019 rights offering 5,976 5,976 Common stock options 182 890 Restricted stock units — 25 7,874 8,597

Warrants (Tables)

Warrants (Tables)	3 Months Ended
	Mar. 31, 2021
Warrants And Rights Note Disclosure [Abstract]
Summary of Warrant Activity	A summary of warrants activity for the three months ended March 31, 2021 is presented below (in thousands, except per share and contractual life data). Number of Shares Weighted Average Exercise Price Per Share Weighted Average Remaining Contractual Life (in Years) Warrants outstanding as of December 31, 2020 7,759 $ 11.66 3.21 Issued — Exercised (67 ) 11.76 Forfeited or expired — Warrants outstanding as of March 31, 2021 7,692 $ 11.75 2.96 Warrants exercisable as of March 31, 2021 7,692 $ 11.75 2.96

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2021
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Summary of Stock Option Activity	A summary of stock option activity under our 2011 Equity Incentive Plan (“2011 Plan”) for the three months ended March 31, 2021 is presented below (in thousands, except per share and contractual life data). Number of Shares Weighted Average Exercise Price Per Share Weighted Average Remaining Contractual Life (in Years) Options outstanding as of December 31, 2020 196 $ 15.48 7.65 Granted — $ — Exercised — $ — Forfeited or expired (14 ) $ 12.95 Options outstanding as of March 31, 2021 182 $ 15.68 7.35 Options exercisable as of March 31, 2021 133 $ 19.79 6.85
Stock-based Compensation Expense	Stock-based compensation expense recognized for stock-based awards in the condensed consolidated statements of operations for the three months ended March 31, 2021 and 2020 was as follows (in thousands): Three Months Ended March 31, 2021 2020 Cost of sales $ — $ — Research and development 5 102 Clinical and regulatory 9 15 Selling and marketing — 41 General and administrative 5 121 Total $ 19 $ 279

Organization and Business Ope_2

Organization and Business Operations - Additional Information (Details) - USD ($) $ / shares in Units, $ in Millions	Mar. 23, 2021	Dec. 08, 2020	May 05, 2020	Mar. 31, 2021	Mar. 31, 2020
Prepaid Expenses and Other Current Assets [Member]
Organization And Business Operations [Line Items]
Deferred costs				$ 0.5
Grant [Member] | National Institutes of Health [Member]
Organization And Business Operations [Line Items]
Net sales				1.6
Grant received funding				6.4
Second Year Grant [Member] | National Institutes of Health [Member]
Organization And Business Operations [Line Items]
Grant received funding				$ 1.4
Chairman Of Board Of Directors [Member]
Organization And Business Operations [Line Items]
Other borrowings		$ 1
Unaffiliated Shareholders [Member]
Organization And Business Operations [Line Items]
Other borrowings		$ 1.2
Number of unaffiliated shareholders		two
Common Stock [Member]
Organization And Business Operations [Line Items]
Number of shares issued upon right offering	4,650,000		7,500,000
Share price (in dollars per share)	$ 6		$ 1
Proceeds from issuance or sale of equity, total	$ 24.5		$ 6.7
Second Sight Medical Products (Switzerland) Sarl [Member]
Organization And Business Operations [Line Items]
Noncontrolling interest, ownership percentage by parent				100.00%	99.50%
Second Sight Medical Products (Switzerland) Sarl [Member] | Executive Officer [Member]
Organization And Business Operations [Line Items]
Noncontrolling interest, ownership percentage by noncontrolling owners					0.50%

Summary of Significant Accounti

Summary of Significant Accounting Policies (Details) $ in Millions	3 Months Ended
	Mar. 31, 2021USD ($)
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]
Reverse stock split	1-for-8
Severance payments	$ 0.2
Argus II Product [Member]
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]
Asset impairment charges	0.7
Argus II Product [Member] | Inventories [Member]
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]
Asset impairment charges	$ 0.5

Concentration of Risk - Additio

Concentration of Risk - Additional Information (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Concentration Risk [Line Items]
Assets	$ 28,145	$ 4,460
Second Sight (Switzerland) Sarl [Member]
Concentration Risk [Line Items]
Assets	$ 62,000	$ 18,000

Fair Value Measurements - Fair

Fair Value Measurements - Fair Value on a Recurring Basis (Details) - Money Market Funds [Member] - Fair Value, Measurements, Recurring [Member] - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Money market funds	$ 26,698	$ 3,122
Level 1 [Member]
Money market funds	$ 26,698	$ 3,122

Selected Balance Sheet Detail -

Selected Balance Sheet Detail - Schedule of Inventories (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Finished goods	$ 295	$ 295
Inventories, gross	295	295
Allowance for excess and obsolete inventory and impairment charge	$ (295)	$ (295)

Selected Balance Sheet Detail_2

Selected Balance Sheet Detail - Schedule of Property and Equipment (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 653	$ 653
Accumulated depreciation and amortization	(499)	(479)
Property and equipment, net	154	174
Laboratory Equipment [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	584	584
Computer Hardware and Software [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 69	$ 69

Selected Balance Sheet Detail_3

Selected Balance Sheet Detail - Additional Information (Details)	Jan. 22, 2021USD ($)ft²	May 18, 2020USD ($)	Mar. 31, 2021USD ($)	Mar. 31, 2020USD ($)	Dec. 31, 2020USD ($)	Dec. 08, 2020USD ($)
Product Information [Line Items]
Accrued interest			$ 82,000		$ 17,000
Estimated incremental borrowing rate			10.00%
Non-cash lease expense			$ 16,000	$ 3,000
Right-of-use assets, net			351,000
Lease liability			366,000
Rent expense			$ 22,000	123,000
Sylmar Biomedical Park, LLC (the “Landlord”) [Member]
Product Information [Line Items]
Termination date of the lease		Jun. 18, 2020
Non-cash lease expense		$ 210,730
Early lease termination fee		150,000
Payments for base rent subject to early termination		$ 900,000
Right-of-use assets, net				2,300,000
Lease liability				2,400,000
Accrued termination fee				150,000
Office space area | ft²	17,290
Sub-lease description	The sub-lease is for two years and two months.
Sylmar Biomedical Park, LLC (the “Landlord”) [Member] | Minimum
Product Information [Line Items]
Operating lease payments	$ 17,000,000
Sylmar Biomedical Park, LLC (the “Landlord”) [Member] | Maximum
Product Information [Line Items]
Operating lease payments	$ 17,500,000
Chairman Of Board Of Directors [Member]
Product Information [Line Items]
Other borrowings						$ 1,000,000
Unaffiliated Shareholders [Member]
Product Information [Line Items]
Other borrowings						$ 1,200,000
Unsecured Promissory Note Payable on December 31, 2021 [Member]
Product Information [Line Items]
Interest rate on unsecured Promissory Note						12.00%
Argus II Product [Member]
Product Information [Line Items]
Other assets impairment charge				$ 700,000

Selected Balance Sheet Detail_4

Selected Balance Sheet Detail - Schedule of Contract Liabilities (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2021USD ($)
Revenue From Contract With Customer [Abstract]
Beginning Balance	$ 335
Consideration received in advance of revenue recognition
Revenue recognized
Ending Balance	$ 335

Selected Balance Sheet Detail_5

Selected Balance Sheet Detail - Schedule of Activity in the Company's Warranty Liabilities (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2021USD ($)
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Beginning balance as of December 31, 2020	$ 200
Additions
Adjustments and other
Ending balance as of March 31, 2021	$ 200

Selected Balance Sheet Detail_6

Selected Balance Sheet Detail - Schedule of Lease Assets and Liabilities (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Organization Consolidation And Presentation Of Financial Statements [Abstract]
2021 (9 months remaining)	$ 153
2022	201
2023	52
Total lease payments	406
Less imputed interest	(40)
Lease liability	366
Current operating lease liabilities	167
Long term operating lease liabilities	199
Total lease liabilities	$ 366
Discount rate	10.00%
Cash paid for operating lease liabilities	$ 17	$ 121

Equity Securities - Anti-diluti

Equity Securities - Anti-dilutive Securities (Details) - shares shares in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities (in shares)	7,874	8,597
Warrants Issued to Underwriter in Connection With May 2020 Offering
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities (in shares)	10
Warrants Issued in Connection With March 2017 Rights Offering
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities (in shares)	1,706	1,706
Warrants Issued in Connection With February 2019 Rights Offering
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities (in shares)	5,976	5,976
Common Stock Options
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities (in shares)	182	890
Restricted Stock Units (RSUs)
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities (in shares)		25

Warrants - Additional Informati

Warrants - Additional Information (Details) $ / shares in Units, $ in Thousands	May 05, 2020$ / sharesshares	Feb. 22, 2019$ / sharesshares	Feb. 15, 2019shares	Mar. 06, 2017$ / sharesshares	Dec. 31, 2019USD ($)	Mar. 31, 2021USD ($)$ / sharesshares	Dec. 31, 2020$ / sharesshares
Class Of Warrant Or Right [Line Items]
Warrant issued	375,000
Number of warrant outstanding						10,125
Warrants exercise price (in dollars per share) | $ / shares	$ 1.25
Warrants expiration date	May 5, 2025
March 2017 Warrants [Member]
Class Of Warrant Or Right [Line Items]
Number of warrants issued			1.7
Adjustment to additional paid-in capital and accumulated deficit | $					$ 1,600
March 2017 Warrants Before Extension [Member] | Risk Free Interest Rate
Class Of Warrant Or Right [Line Items]
Alternative investment, measurement input			2.50
March 2017 Warrants Before Extension [Member] | Expected Volatility [Member]
Class Of Warrant Or Right [Line Items]
Alternative investment, measurement input			81
March 2017 Warrants Before Extension [Member] | Expected Lives [Member]
Class Of Warrant Or Right [Line Items]
Alternative investment, measurement input			3 years 29 days
March 2017 Warrants Before Extension [Member] | Dividend Yield [Member]
Class Of Warrant Or Right [Line Items]
Alternative investment, measurement input			0
March 2017 Warrants After Extension [Member] | Risk Free Interest Rate
Class Of Warrant Or Right [Line Items]
Alternative investment, measurement input			2.49
March 2017 Warrants After Extension [Member] | Expected Volatility [Member]
Class Of Warrant Or Right [Line Items]
Alternative investment, measurement input			82
March 2017 Warrants After Extension [Member] | Expected Lives [Member]
Class Of Warrant Or Right [Line Items]
Alternative investment, measurement input			5 years 29 days
March 2017 Warrants After Extension [Member] | Dividend Yield [Member]
Class Of Warrant Or Right [Line Items]
Alternative investment, measurement input			0
Warrant [Member]
Class Of Warrant Or Right [Line Items]
Number of warrant outstanding						7,692,000	7,759,000
Warrants exercise price (in dollars per share) | $ / shares						$ 11.75	$ 11.66
Warrants exercisable, intrinsic value | $						$ 71,000
Right Offering
Class Of Warrant Or Right [Line Items]
Number of shares issued upon right offering		5,976,000		1,706,000
Share price (in dollars per share) | $ / shares		$ 5.792		$ 11.76
Additional share price (in dollars per share) | $ / shares		$ 11.76		$ 11.76
Term of warrants		5 years		5 years
Right Offering | March 2017 Warrants [Member]
Class Of Warrant Or Right [Line Items]
Term of warrants			2 years

Warrants - Summary of Warrants

Warrants - Summary of Warrants Activity (Details) - $ / shares	May 05, 2020	Mar. 31, 2021	Dec. 31, 2020
Class of Warrant or Right, Outstanding [Roll Forward]
Warrant issued	375,000
Outstanding at ending		10,125
Class of Warrant or Right, Exercise Price of Warrants or Rights [Roll Forward]
Outstanding at ending	$ 1.25
Warrant [Member]
Class of Warrant or Right, Outstanding [Roll Forward]
Outstanding at beginning		7,759,000
Exercised		(67,000)
Outstanding at ending		7,692,000	7,759,000
Exercisable at ending		7,692,000
Class of Warrant or Right, Exercise Price of Warrants or Rights [Roll Forward]
Outstanding at beginning		$ 11.66
Exercised		11.76
Outstanding at ending		11.75	$ 11.66
Exercisable at ending		$ 11.75
Class of Warrant or Right, Weighted Average Remaining Contractual Life of Warrants or Rights [Roll Forward]
Outstanding at ending		2 years 11 months 15 days	3 years 2 months 15 days
Exercisable at ending		2 years 11 months 15 days

Stock-Based Compensation - Summ

Stock-Based Compensation - Summary of Stock Option Activity (Details) - 2011 Equity Incentive Plan - Employee Stock Option - $ / shares shares in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2021	Dec. 31, 2020
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options outstanding, number of shares (in shares)	196
Forfeited or expired, number of shares (in shares)	(14)
Options outstanding, number of shares (in shares)	182	196
Options exercisable, number of shares (in shares)	133
Options outstanding, weighted average exercise price (in dollars per share)	$ 15.48
Forfeited or expired, weighted average exercise price (in dollars per share)	12.95
Options outstanding, weighted average exercise price (in dollars per share)	15.68	$ 15.48
Options exercisable, weighted average exercise price (in dollars per share)	$ 19.79
Options outstanding, weighted average remaining contractual life (Year)	7 years 4 months 6 days	7 years 7 months 24 days
Options exercisable, weighted average remaining contractual life (Year)	6 years 10 months 6 days

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Details)	3 Months Ended
	Mar. 31, 2021USD ($)shares
2011 Equity Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Intrinsic value of stock options exercisable	$ 160,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options	$ 100,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	2 years 8 months 12 days
The 2015 Employee Stock Purchase Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized | shares	77,031

Stock-based Compensation - Stoc

Stock-based Compensation - Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Allocated share-based compensation expense	$ 19	$ 279
Research and Development
Allocated share-based compensation expense	5	102
Clinical and Regulatory
Allocated share-based compensation expense	9	15
Selling and Marketing
Allocated share-based compensation expense		41
General and Administrative
Allocated share-based compensation expense	$ 5	$ 121

Litigation, Claims and Assess_2

Litigation, Claims and Assessments - Additional Information (Details) - USD ($)	Apr. 01, 2021	Mar. 31, 2021
Loss Contingencies [Line Items]
Demanded damages, value		$ 7,300,000
Subsequent Event [Member]
Loss Contingencies [Line Items]
Liquidation damages	$ 1,000,000
Subsequent Event [Member] | Oppenheimer And Co Inc
Loss Contingencies [Line Items]
Business Combination,Commission Percentage	6.50%
Invoice amount, receivable	$ 1,860,000
Private placement, amount raised	$ 27,900,000